Details for Patent: 8,784,882

Which drugs does patent 8,784,882 protect, and when does it expire?

Patent 8,784,882 protects NATESTO and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 8,784,882

Title:	Controlled release delivery system for nasal applications and method of treatment
Abstract:	This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Inventor(s):	Mattern; Claudia (Stans, CH)
Assignee:	Mattern Pharma AG (Vaduz, LI)
Application Number:	13/194,853
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form; Delivery; Device;

Drugs Protected by US Patent 8,784,882

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014		RX	Yes	Yes			Y			A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

International Family Members for US Patent 8,784,882

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047722
Austria	319426
Australia	2004286781
Brazil	PI0416370
Canada	2541498